- Q3 2026 net loss narrowed to $96.3M ($0.57/share) from $163.1M ($1.17/share) in Q3 2025.
- Total cash, cash equivalents and investments ended the quarter at approximately $901M.
- ECLIPSE 1 Phase 3 topline data expected in Q4 2026; Gilead collaboration announced.
Signal #134622 · SEC 8-K
$VIR SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $VIR filing catalyst
Why did $VIR trigger an AI stock catalyst alert?
$VIR triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +1.5/10). Headline: Vir Biotechnology Reports Q3 2026 Loss of $0.57 Per Share, Details Gilead Deal. Key points: - Q3 2026 net loss narrowed to $96.3M ($0.57/share) from $163.1M ($1.17/share) in Q3 2025. - Total cash, cash equivalents and investments ended the quarter at approximately $901M. - ECLIPSE 1 Phase 3 topline data expected in Q4 2026; Gilead collaboration announced.
How did $VIR stock react after the SEC filing?
After the SEC 8-K for $VIR, observed market reaction: T0 price $11.77. Past moves do not guarantee future results.
Where can I get real-time $VIR SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $VIR via Telegram and the VIP Web Terminal from €10/month.